AI Tool Decodes Brain Cancer's Genome During Surgery 4
An anonymous reader quotes a report from Harvard Medical School: Scientists have designed an AI tool that can rapidly decode a brain tumor's DNA to determine its molecular identity during surgery -- critical information that under the current approach can take a few days and up to a few weeks. Knowing a tumor's molecular type enables neurosurgeons to make decisions such as how much brain tissue to remove and whether to place tumor-killing drugs directly into the brain -- while the patient is still on the operating table. A report on the work, led by Harvard Medical School researchers, is published July 7 in the journal Med.
The tool, called CHARM (Cryosection Histopathology Assessment and Review Machine), is freely available to other researchers. It still has to be clinically validated through testing in real-world settings and cleared by the FDA before deployment in hospitals, the research team said. [...] CHARM was developed using 2,334 brain tumor samples from 1,524 people with glioma from three different patient populations. When tested on a never-before-seen set of brain samples, the tool distinguished tumors with specific molecular mutations at 93 percent accuracy and successfully classified three major types of gliomas with distinct molecular features that carry different prognoses and respond differently to treatments.
Going a step further, the tool successfully captured visual characteristics of the tissue surrounding the malignant cells. It was capable of spotting telltale areas with greater cellular density and more cell death within samples, both of which signal more aggressive glioma types. The tool was also able to pinpoint clinically important molecular alterations in a subset of low-grade gliomas, a subtype of glioma that is less aggressive and therefore less likely to invade surrounding tissue. Each of these changes also signals different propensity for growth, spread, and treatment response. The tool further connected the appearance of the cells -- the shape of their nuclei, the presence of edema around the cells -- with the molecular profile of the tumor. This means that the algorithm can pinpoint how a cell's appearance relates to the molecular type of a tumor.
The tool, called CHARM (Cryosection Histopathology Assessment and Review Machine), is freely available to other researchers. It still has to be clinically validated through testing in real-world settings and cleared by the FDA before deployment in hospitals, the research team said. [...] CHARM was developed using 2,334 brain tumor samples from 1,524 people with glioma from three different patient populations. When tested on a never-before-seen set of brain samples, the tool distinguished tumors with specific molecular mutations at 93 percent accuracy and successfully classified three major types of gliomas with distinct molecular features that carry different prognoses and respond differently to treatments.
Going a step further, the tool successfully captured visual characteristics of the tissue surrounding the malignant cells. It was capable of spotting telltale areas with greater cellular density and more cell death within samples, both of which signal more aggressive glioma types. The tool was also able to pinpoint clinically important molecular alterations in a subset of low-grade gliomas, a subtype of glioma that is less aggressive and therefore less likely to invade surrounding tissue. Each of these changes also signals different propensity for growth, spread, and treatment response. The tool further connected the appearance of the cells -- the shape of their nuclei, the presence of edema around the cells -- with the molecular profile of the tumor. This means that the algorithm can pinpoint how a cell's appearance relates to the molecular type of a tumor.
False headline (from Harvard article) (Score:5, Informative)
Seriously I expected better. It doesn't "decode the genome" .. it looks at the cells and, by the phenotypic characteristics of the cell, determines that there must be mutations in a certain specific (and few) genes. It doesn't decode the genome, not by a long shot. It's literally like looking at a green eyed person and saying they have an alteration in the eye color gene.
Re: False headline (from Harvard article) (Score:1)
CHARM? software? (Score:1)
I wonder what the authors behind this paper were thinking naming their software CHARM (Cryosection Histopathology Assessment and Review Machine) - the last word clearly highlights how the full name of the software was tortured to produce the snappy acronym.
https://en.wikipedia.org/wiki/... [wikipedia.org] - is the software for which Martin Karplus shared his Nobel Prize (how many times Nobel Prize was given to computational biologists, by the way? I counted one) with Michael Levitt.
Dupe (Score:2)